ScreenerHero

CSTL Castle Biosciences, Inc.

NAS · US · Healthcare · Diagnostics & Research · castlebiosciences.com
33.71USD+2.15%Mkt Cap: 1.03B $P/E: —

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The compan…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$241.07BUSDP/E 35.1
DHR
Danaher Corporation
$152.87BUSDP/E 38.8
NTRA
Natera, Inc.
$56.33BUSD
A
Agilent Technologies, Inc.
$47.41BUSDP/E 33.2
LONN
Lonza Group AG
$44.91BUSDP/E 37.3
IQV
IQVIA Holdings Inc.
$42.61BUSDP/E 32.2
WAT
Waters Corporation
$42.13BUSDP/E 108.6
IDXX
IDEXX Laboratories, Inc.
$40.48BUSDP/E 36.1
ILMN
Illumina, Inc.
$39.95BUSDP/E 49.4
MTD
Mettler-Toledo International Inc.
$30.65BUSDP/E 34.5
LH
Labcorp Holdings Inc.
$25.48BUSDP/E 26.0
DGX
Quest Diagnostics Incorporated
$25.48BUSDP/E 24.5
GH
Guardant Health, Inc.
$22.22BUSD
RVTY
Revvity, Inc.
$16.98BUSDP/E 72.8
MEDP
Medpace Holdings, Inc.
$16.82BUSDP/E 35.4
ERF
Eurofins Scientific SE
$14.08BUSDP/E 26.3
CRL
Charles River Laboratories International, Inc.
$14.23BUSD
ICLR
ICON Public Limited Company
$12.69BUSDP/E 173.2
BIM
bioMérieux S.A.
$10.31BUSDP/E 20.6
QGEN
Qiagen N.V.
$9.20BUSDP/E 22.6

Key Statistics

Company
Market Cap1.03B USD
Enterprise Value777.98M USD
Revenue (TTM)357.28M USD
Gross Profit273.20M USD
Net Income (TTM)-24.16M USD
Revenue/Share12.04 USD
Last Price33.71 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.0K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-35.90
PEG—
EV/EBITDA-47.10
EV/Revenue2.18
P/S2.88
P/B2.19
EPS (TTM)-0.64
EPS (Forward)-0.94
52W Range
17.7260% of range44.28
52W High44.28 USD
52W Low17.72 USD
Profitability
Gross Margin79.37%
Oper. Margin-2.96%
EBITDA Margin-4.62%
Profit Margin-7.02%
ROE-5.13%
ROA-4.18%
Growth
Revenue Growth20.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF64.35M USD
CapEx (TTM)36.02M USD
FCF Margin-2.03%
FCF Yield-0.70%
Net Debt-230.15M USD
Net Debt/EBITDA13.94
Balance Sheet
Debt/Equity0.08
Current Ratio6.04
Quick Ratio5.60
Book Value/Sh15.41 USD
Cash/Share8.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)45.22 USD
Upside (mean)+34.2%
Target Range35.00 USD – 57.00 USD
35.00+34.2% to mean57.00
# Analysts9
Ownership
Shares Out.30.55M
Float27.15M
Insiders2.40%
Institutions91.01%
Short Interest
Short Ratio5.7d
Short % Float6.37%
Short % Out.6.22%
Shares Short1.90M
Short (prev mo.)1.75M
Technical
SMA 5033.11 (+1.8%)
SMA 20028.98 (+16.3%)
Beta0.94
S&P 52W Chg15.84%
Avg Vol (30d)364.64K
Avg Vol (10d)402.59K
Technical Indicators
RSI (14)49.8
MACD0.6801
MACD Signal1.1061
MACD Hist.-0.4260
BB Upper37.20 USD
BB Middle34.54 USD
BB Lower31.89 USD
BB Width15.37%
ATR (14)1.714 USD
Vol Ratio (20d)1.02x